Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: Breast Cancer Research

Université Laval

$100,000.00

Pre-clinical pharmacokinetic and efficacy assays with an efficient 17beta-hydroxysteroid dehydrogenase type 7 inhibitor for breast cancer therapy

EF 2023-24

Résumé
Breast cancer (BC) is the most common cancer in women, of which 70% are estrogen dependent. It is thus important to control the potent estrogen estradiol (E2) in therapies. Our previous research showed that 17beta-hydroxysteroid dehydrogenase type 7 (17beta-HSD7) activates estrogen while inactivating the most potent androgen dihydrotestosterone (DHT) in BC cells, the enzyme thus being a natural target for such BC treatment. Our research showed that E2 levels were significantly reduced and DHT levels increased using 17beta-HSD7 inhibitors in BC cells, shrinking the xenograft tumors, decreasing cancer cell density, and reducing 17beta-HSD7 expression. In recent work, we have further improved the inhibitor's efficiency in animal assays with MCF7 and T47D xenograft models thanks to the support of our partner Antel Holding Group, and our results have demonstrated significant drug efficiency to shrink tumors in animal models. Animal toxicity was also tested and non-apparent after weekly subcutaneous injections in mice for 3 weeks. We noted no effect of the inhibitor on the weight of the liver, kidneys, ovaries, and uterus. We therefore believe that this is a very promising option for the development of new, efficient, and safe treatments for BC, which will benefit the high number of women who are faced with this diagnosis every year and lighten the load on the healthcare system by reducing the number of serious and/or fatal cases. In the last years, we have demonstrated the efficacy of our novel inhibitor INH7-464 and its low toxicity in BC cells and xenograft tumor animal models, obtaining a provisional patent, followed by a patent collaborative treat application with positive feedback. We will carry out detailed pharmacological study including drug absorption, distribution, metabolism and excretion, and study of the oral administration of the inhibitor. A serial of measures will be attempted for facilitating the commercialization.
Programme
Project Grant - PA: Breast Cancer Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
494899
Name
Lin Sheng-Xiang
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Commercialization
Projecttitle
Pre-clinical pharmacokinetic and efficacy assays with an efficient 17beta-hydroxysteroid dehydrogenase type 7 inhibitor for breast cancer therapy
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Drug Absorption, Distribution, Metabolism And Excretion; Drug Efficacy And Toxicity; Hormone-Dependent Breast Cancer; Joint Targeting Of Sex-Hormone Syntheses; Pre-Clinical Assay Of An Efficient 17beta-Hsd7 Inhibitor; Pre-Clinical Pharmaco-Kinetics; Reductive 17beta-Hudroxysteroid Dehydrogenases; Serum Sex-Hormone Balancing; Synergy Of Breast Cancer Drugs; Xenograft Tumor Shrinkage
Abstract
Breast cancer (BC) is the most common cancer in women, of which 70% are estrogen dependent. It is thus important to control the potent estrogen estradiol (E2) in therapies. Our previous research showed that 17beta-hydroxysteroid dehydrogenase type 7 (17beta-HSD7) activates estrogen while inactivating the most potent androgen dihydrotestosterone (DHT) in BC cells, the enzyme thus being a natural target for such BC treatment. Our research showed that E2 levels were significantly reduced and DHT levels increased using 17beta-HSD7 inhibitors in BC cells, shrinking the xenograft tumors, decreasing cancer cell density, and reducing 17beta-HSD7 expression. In recent work, we have further improved the inhibitor's efficiency in animal assays with MCF7 and T47D xenograft models thanks to the support of our partner Antel Holding Group, and our results have demonstrated significant drug efficiency to shrink tumors in animal models. Animal toxicity was also tested and non-apparent after weekly subcutaneous injections in mice for 3 weeks. We noted no effect of the inhibitor on the weight of the liver, kidneys, ovaries, and uterus. We therefore believe that this is a very promising option for the development of new, efficient, and safe treatments for BC, which will benefit the high number of women who are faced with this diagnosis every year and lighten the load on the healthcare system by reducing the number of serious and/or fatal cases. In the last years, we have demonstrated the efficacy of our novel inhibitor INH7-464 and its low toxicity in BC cells and xenograft tumor animal models, obtaining a provisional patent, followed by a patent collaborative treat application with positive feedback. We will carry out detailed pharmacological study including drug absorption, distribution, metabolism and excretion, and study of the oral administration of the inhibitor. A serial of measures will be attempted for facilitating the commercialization.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lin, Sheng-Xiang
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~